Indication

Monotherapy for the treatment of adult patients with recurrent or advanced mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer (EC) that has progressed on or following prior treatment with a platinum‑containing regimen.

Medicine details

Medicine name:
dostarlimab (Jemperli)
SMC ID:
SMC2404
Pharmaceutical company
GlaxoSmithKline UK Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
17 January 2022
SMC meeting date:
07 December 2021
Patient group submission deadline:
01 November 2021